Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
InMed Provides Update on BayMedica Commercial Business Newsfile - Fri Dec 12, 4:40PM CST

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.3150 (+9.58%)
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 Newsfile - Tue Nov 18, 6:32AM CST

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Vancouver,...

INM : 1.3150 (+9.58%)
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update Newsfile - Thu Nov 6, 4:06PM CST

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a...

INM : 1.3150 (+9.58%)
InMed Pharmaceuticals Strengthens Board with Strategic Appointment Tipranks - Fri Oct 17, 8:18AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. InMed Pharmaceuticals...

INM : 1.3150 (+9.58%)
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors Newsfile - Thu Oct 16, 7:40AM CDT

Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.3150 (+9.58%)
InMed Pharmaceuticals Strengthens Board with Appointment of Industry Veteran Neil Klompas Tipranks - Fri Oct 10, 8:17AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

INM : 1.3150 (+9.58%)
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors Newsfile - Thu Oct 9, 7:38AM CDT

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.3150 (+9.58%)
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update Newsfile - Tue Sep 23, 7:44AM CDT

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathologyFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related...

INM : 1.3150 (+9.58%)
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Newsfile - Fri Sep 5, 1:04PM CDT

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 1.3150 (+9.58%)
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 Newsfile - Mon Jul 28, 6:02AM CDT

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activityVancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:...

INM : 1.3150 (+9.58%)

Barchart Exclusives

This High-Yield Dividend Stock Trades at a Third of Its Record Highs: Is It a Buy for 2026? Barchart - 26 minutes ago
Nike stock has a dividend yield of 2.4% and trades at a third of its 2021 highs. The stock could, however, see upside next year as it progresses on the turnaround strategy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot